相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System
Jorge Cortes et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Discontinuation of tyrosine kinase therapy in CML
Francois-Xavier Mahon
ANNALS OF HEMATOLOGY (2015)
Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization
Nicholas C. P. Cross et al.
ANNALS OF HEMATOLOGY (2015)
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries
V. S. Hoffmann et al.
LEUKEMIA (2015)
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
David T. Yeung et al.
BLOOD (2015)
Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors
Peter Valent et al.
BLOOD (2015)
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
Elias Jabbour et al.
BLOOD (2014)
How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia
David M. Ross et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Deep Molecular Response in Chronic Myeloid Leukemia: The New Goal of Therapy?
Francois-Xavier Mahon et al.
CLINICAL CANCER RESEARCH (2014)
Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy
Gabriel Etienne et al.
HAEMATOLOGICA (2014)
Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome?
Johan Richter et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV
Ruediger Hehlmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia
Domenico Russo et al.
BLOOD (2013)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani et al.
BLOOD (2013)
Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry
Martin Hoglund et al.
BLOOD (2013)
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Camille Abboud et al.
BLOOD (2013)
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M. Ross et al.
BLOOD (2013)
Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON)
Noortje Thielen et al.
EUROPEAN JOURNAL OF CANCER (2013)
Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib
T. D. Kim et al.
LEUKEMIA (2013)
Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis
F. J. Giles et al.
LEUKEMIA (2013)
Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib
Alfonso Quintas-Cardama et al.
LEUKEMIA RESEARCH (2013)
Treatment-, Patient-, and Disease-Related Factors and the Emergence of Adverse Events with Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
Elizabeth Irvine et al.
PHARMACOTHERAPY (2013)
Which TKI? An embarrassment of riches for chronic myeloid leukemia patients
Timothy Hughes et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2013)
Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond
Wesam Ahmed et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2013)
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
Hagop M. Kantarjian et al.
BLOOD (2012)
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
Hagop Kantarjian et al.
BLOOD (2012)
Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: A systematic review of efficacy and safety data
Massimo Breccia et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2012)
Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy
P. J. Shami et al.
LEUKEMIA (2012)
Standardized definitions of molecular response in chronic myeloid leukemia
N. C. P. Cross et al.
LEUKEMIA (2012)
Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia
Juan Luis Steegmann et al.
LEUKEMIA & LYMPHOMA (2012)
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
Simona Soverini et al.
BLOOD (2011)
Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population
Fabio Efficace et al.
BLOOD (2011)
Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment
Su Chu et al.
BLOOD (2011)
Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease
Jean-Claude Chomel et al.
BLOOD (2011)
Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?
Elias Jabbour et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia
Ruediger Hehlmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib
Carlo Gambacorti-Passerini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
David Marin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP
Nicoletta Testoni et al.
BLOOD (2009)
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study
Lucien Noens et al.
BLOOD (2009)
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2009)
Chronic myeloid leukaemia
Ruediger Hehlmann et al.
LANCET (2007)
分享论文
